# CVS Shares Trade Below Wall Street Targets

> CVS Health stock trades near $94, 19% below analyst target and 50% below model's $141 base case
- Title: CVS Shares Trade Below Wall Street Targets · Yahoo Finance
- Summary: CVS Health stock trades near $94, 19% below analyst target and 50% below model's $141 base case CVS Health's valuation gap persists due to strong earnings…
- Keywords: cvs health, seahawks, nfl, wall street, analyst targets, forward p/e, aetna, pbm, drug pricing, operating cash flow, q2 earnings, 2026 earnings
- Source: Yahoo Finance — https://finance.yahoo.com/markets/stocks/articles/cvs-trading-well-below-wall-144011771.html
- Published: 2026-09-16T14:40:11+00:00
- Read time: 1 min
- Topics: cvs health, seahawks, nfl, wall street, analyst targets, forward p/e, aetna, pbm, drug pricing, operating cash flow, q2 earnings, 2026 earnings
## Current Price Gap
CVS Health trades near $94, 19% below $116 analyst target and 50% below $141 model base case
## Recent Earnings Boost
Q2 earnings beat consensus by 38% with Aetna's medical benefit ratio improving to 87.4%
## Management Guidance
Raised 2026 adjusted EPS to $7.90-$8.10 range and operating cash flow to at least $11.5 billion
## Valuation Gap
Forward P/E of 11x suggests potential for 49.6% upside from current price to $141 base case
## PBM Threats
340 billion pressure and lower selling season retention threaten to undermine earnings growth
## Regulatory Risks
PBM re-regulation and drug pricing rules could escalate if political appetite increases
## Next Checkpoint
Q3 2026 earnings expected November 4, 2026 with focus on Aetna's medical benefit ratio
## Key takeaway

CVS Health's valuation gap persists due to strong earnings but concerns about PBM regulation and drug pricing rules